Alternative Dosing and Regimen of Replagal to Treat Fabry Disease

Completed

Phase 2 Results N/A

Summary of Purpose

The main goal of this study is to assess the pharmacodynamic effects of different or more frequent doses of Replagal compared to the standard dosing regimen. Replagal is a genetically engineered form of alpha-Galactosidase A, an enzyme that normally breaks down a fatty substance called globotriaosylceramide (Gb(3)). In patients with Fabry disease, GB(3) does not function properly and therefore builds up causing...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 3 March 2008.

1 Jan 2004 6 Jan 2004 Unavailable 1 Nov 2005 1 Nov 2005 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study

Contacts

Not available